Want to see CAMP full AI Analyst Report?
CAMP Stock Chart & Stats
$4.20
$0.15(4.98%)
At close: 4:00 PM EDT
$4.20
$0.15(4.98%)
Day’s Range― - ―
52-Week Range$1.46 - $7.75
Previous Close$4.45
Volume169.64K
Average Volume (3M)237.17K
Market Cap
$281.76M
Enterprise Value$168.40
Total Cash (Recent Filing)$87.13M
Total Debt (Recent Filing)$2.37M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Nov 19, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding62,753,200
10 Day Avg. Volume270,731
30 Day Avg. Volume237,174
Financial Highlights & Ratios
PEG Ratio6.15
Price to Book (P/B)3.90
Price to Sales (P/S)53.24
P/FCF Ratio-6.24
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.10Price Target Upside116.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.06
Revenue Forecast (FY)$6.99M
Bulls Say, Bears Say
Bulls Say
Improving Revenue And Gross MarginHigher revenue and substantially improved gross margin indicate better economics in the company’s commercial activities. If sustained, this can improve the contribution from future products and provide a stronger foundation as clinical programs advance.
Major Financing Strengthens Development RunwayThe substantial capital raise gives CAMP4 resources to fund CMP-002 and other pipeline programs over the medium term. Greater liquidity can support trial execution, reduce immediate funding pressure, and preserve strategic flexibility during development.
Regulatory Clearance Enables Lead Clinical TrialClearance to begin a first-in-human study advances CAMP4 from preclinical work toward clinical validation in an underserved disorder with no approved treatments. Trial execution can generate important evidence for the platform and support future development decisions.
Bears Say
Severe Operating And Net LossesThe scale of operating and net losses remains disproportionate to current revenue, showing that the business has not yet achieved operating leverage. Continued losses could require substantial future financing before product commercialization or recurring revenue is established.
Persistent Cash Burn Requires External FundingNegative operating and free cash flow means CAMP4 cannot currently fund its operations internally. Although recent financing improves runway, ongoing clinical investment will likely maintain dependence on capital markets and could expose the company to funding or dilution risk.
Negative Equity And Potential DilutionNegative equity weakens financial flexibility and signals that accumulated losses have eroded the capital base. Additional equity financing and employee awards may support development and hiring, but can dilute existing holders while the company remains loss-making.
CAMP4 Therapeutics Corporation News
CAMP FAQ
What was CAMP4 Therapeutics Corporation’s price range in the past 12 months?
CAMP4 Therapeutics Corporation lowest stock price was $1.46 and its highest was $7.75 in the past 12 months.
What is CAMP4 Therapeutics Corporation’s market cap?
CAMP4 Therapeutics Corporation’s market cap is $281.76M.
When is CAMP4 Therapeutics Corporation’s upcoming earnings report date?
CAMP4 Therapeutics Corporation’s upcoming earnings report date is Nov 19, 2026 which is in 75 days.
How were CAMP4 Therapeutics Corporation’s earnings last quarter?
CAMP4 Therapeutics Corporation released its earnings results on Aug 14, 2026. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.211 by -$0.369.
Is CAMP4 Therapeutics Corporation overvalued?
According to Wall Street analysts CAMP4 Therapeutics Corporation’s price is currently Undervalued.
Does CAMP4 Therapeutics Corporation pay dividends?
CAMP4 Therapeutics Corporation does not currently pay dividends.
What is CAMP4 Therapeutics Corporation’s EPS estimate?
CAMP4 Therapeutics Corporation’s EPS estimate is -0.17.
How many shares outstanding does CAMP4 Therapeutics Corporation have?
CAMP4 Therapeutics Corporation has 62,753,200 shares outstanding.
What happened to CAMP4 Therapeutics Corporation’s price movement after its last earnings report?
CAMP4 Therapeutics Corporation reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.211. Following the earnings report the stock price went up 20.889%.
Which hedge fund is a major shareholder of CAMP4 Therapeutics Corporation?
Currently, no hedge funds are holding shares in CAMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CAMP4 Therapeutics Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.10 (116.67% Upside)
$9.10 (116.67% Upside)
Blogger Sentiment
Bullish
CAMP Sentiment 60%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
197.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
82.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
CAMP Stock 12 Month Forecast
Average Price Target
$9.10
▲(116.67% Upside)
Technical Analysis
Relmada Therapeutics
―
Beyondspring
―
MiNK Therapeutics
―
Artiva Biotherapeutics, Inc.
―
OS Therapies Incorporated
―
Ownership Overview
22.37% Insiders
6.50% Mutual Funds
34.74% Other Institutional Investors
32.02% Public Companies and
Individual Investors